Abstract
Background An FMR1 full mutation, which causes Fragile X Syndrome, is defined as >200 repeats of the CGG motif in the gene’s 5’ untranslated region. A repeat count in the range 55-200 is considered an FMR1 premutation (PM) and was previously associated with neuropsychiatric phenotypes. However, these associations did not always replicate and may be due to ascertainment bias. Here, we studied the association between PM and attention deficit hyperactivity disorder (ADHD) and anxiety using large population-based screening data.
Methods We used data on women who underwent genetic screening in Rabin Medical Center in Israel for family planning purposes between 2001-2020. PM carriers were defined as subjects with 58-200 CGG repeats. We linked the genetic testing results to longitudinal electronic medical records (EMR) from Clalit Health Services. We defined ADHD and anxiety based on either a formal diagnosis or the purchase of relevant medications. As a positive control, we considered premature ovarian insufficiency (POI) and high follicle-stimulating hormone (FSH) levels before the age of 40. Our primary analysis used Cox regression with socioeconomic status, immigration, and age at testing as covariates.
Results Our sample included 53,707 women: 464 PM carriers and 53,243 non-carriers. PM was associated with POI (hazard ratio (HR): 4.08, 95% confidence interval (CI): 2.16-7.72) and high FSH (HR: 3.43, 95% CI: 2.65-4.43). However, PM was not associated with either ADHD (HR 0.95; 95% CI: 0.51-1.77; 1331 events) or anxiety (HR 0.81; 95% CI: 0.47-1.39; 1814 events). The results were similar when the phenotype was defined based on medications and with logistic regression. Our study was sufficiently powered to detect HR about 2 or higher.
Discussion We found no association between PM and either ADHD or anxiety. Our study is less prone to ascertainment bias towards affected families; however, the ascertained subjects are likely healthier than the population average. While our sample size is the largest to date, given the low frequency of PM carriers, small effects cannot be excluded.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
L.K. was supported by a United States-Israel Binational Science Foundation grant no. 2017024 to S.C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of Rabin Medical Center, approval number 0197-20.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The electronic medical records analyzed as part of this study are unavailable to external researchers.
